Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 149 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 16728
Sealed predictions
- MRS2 in dopamine neurons, braak+0.33 (p 0.389) → -0.29 (p 0.443)receipt 16735
Swarm cases
receipt 16735: MRS2 in dopamine neurons, braak
- power
- full sample +0.01 (p 0.983, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.807, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.585, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.10, sign flips 8; without severely affected donors +0.01 (p 0.983, n 18). fragile.
- cell type
- strongest in microglia: -0.67 (p 0.0024, n 18) vs +0.01 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MRS2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MRS2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.18 p 0.534 (needs p < 1.4e-4)
Receipts
loading the receipts